FDA Approves First Myasthenia Gravis Treatment for Children
13 Mar 2025
In a groundbreaking move, the U.S. Food and Drug Administration (FDA) has approved Soliris (eculizumab) for children aged six and older with generalized myasthenia gravis (gMG), marking the first treatment available for pediatric patients with this challenging autoimmune neuromuscular disorder. This decision brings a ray of hope to families affected...
Read More
